Aperiomics CEO Dr. Crystal Icenhour to Present the Future of Technology in Pathogen Identification at Biotech Showcase in San Francisco

Aperiomics CEO Dr. Crystal Icenhour to Present the Future of Technology

in Pathogen Identification at Biotech Showcase in San Francisco


— Monday, January 8, 9:00 a.m., Franciscan – B (Ballroom Level) of Hilton —


Ashburn, VA –, January 2, 2017 – Dr. Crystal Icenhour, an expert in infectious disease diagnostics, will present her vision for the latest technology, deep shotgun metagenomic sequencing, to identify all known pathogens during the Biotech Showcase, January 8, in San Francisco.


Icenhour, CEO of Aperiomics, is changing the healthcare industry’s thinking regarding pathogen testing. Her presentation will introduce Aperiomics’ ground-breaking technology to strategic partners, potential investors and other attendees. She and her team have redefined the way in which infectious diseases are detected (through proprietary analysis of terabytes of data using DNA mapping).


Today, up to 75% of infections are never accurately diagnosed, wasting time and millions of dollars spent in trial-and-error testing and ineffective medications.  Aperiomics identifies every known pathogen (bacteria, virus, fungi and parasite) in a single test through deep shotgun metagenomic sequencing of the DNA or RNA in any sample (patient, environmental, etc.).  No other company in the world can do this.


Icenhour holds two patents, has authored numerous research articles and is a prolific speaker at scientific conferences.  She has served on review panels for the NSF, the EPA and NIH.  She is an adjunct professor of medicine at Duke University Medical Center.  Dr. Icenhour received her PhD in Pathobiology and Molecular Medicine from the University of Cincinnati Medical School.  She trained as a postdoctoral fellow in the Thoracic Diseases Research Unit at the Mayo Clinic, as well as in the Infectious Disease Department at Duke University Medical Center.  Additionally, she is well-versed in entrepreneurship, biotechnology business and politics, and women in business.


About Aperiomics


Aperiomics is the only company identifying every bacteria, DNA virus, fungi and parasite in one test.  Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through deep shotgun metagenomic sequencing of the DNA in any sample (patient, environmental, etc.).  The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens.  This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about our successes in helping others.  Aperiomics is supported by the National Science Foundation and was named Life Sciences Innovators of the Year in 2016 and a finalist in the 2017 Greater Washington Innovation Awards.  For more information, visit www.aperiomics.com or call (703) 229-0406.